SCHEMBL8544302

SCHEMBL8544302

CCOC(=O)/C(C#N)=C/c1ccccc1C(F)(F)F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.60
LMNA P02545 3/20 0.60
MAPT P10636 7/20 0.57
ALDH1A1 P00352 7/20 0.57
MIF P14174 1/20 0.56
ATM Q13315 1/20 0.56
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
STAT1 P42224 1/20 0.55
POLB P06746 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
PDCD1 Q15116 1/20 0.51
CD274 Q9NZQ7 1/20 0.51
TP53 P04637 2/20 0.51
KDM4E B2RXH2 2/20 0.50
NPSR1 Q6W5P4 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
CRHBP P24387 1/20 0.48
CRHR2 Q13324 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8544307 1.00 SMN1; SMN2 (0.60) SMN1; SMN2LMNAMAPTALDH1A1MIF
SCHEMBL11669632 1.00 SMN1; SMN2 (0.60) SMN1; SMN2LMNAMAPTALDH1A1MIF
SCHEMBL9458765 0.88 MAPT (0.53) SMN1; SMN2LMNAMAPTALDH1A1MIF
SCHEMBL9458769 0.88 MAPT (0.53) SMN1; SMN2LMNAMAPTALDH1A1MIF
SCHEMBL17351445 0.83 MAPT (0.61) SMN1; SMN2LMNAMAPTALDH1A1MIF
SCHEMBL12670733 0.83 MAPT (0.61) SMN1; SMN2LMNAMAPTALDH1A1MIF
SCHEMBL12677357 0.83 MAPT (0.61) SMN1; SMN2LMNAMAPTALDH1A1MIF
SCHEMBL11782981 0.82 LMNA (0.61) SMN1; SMN2LMNAMAPTPOLBTDP1
SCHEMBL2791456 0.82 ALDH1A1 (0.63) SMN1; SMN2LMNAMAPTALDH1A1MIF
SCHEMBL2791458 0.82 ALDH1A1 (0.63) SMN1; SMN2LMNAMAPTALDH1A1MIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947707-B2 Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-05-24 US disclosed
US-20090306396-A1 NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-1932833-A1 NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Kissei Pharmaceutical Co., Ltd. (JP) 2008-06-18 EP disclosed
EP-0537949-B1 Antiproliferative derivatives of 4H-naphtho 1,2-b pyran LILLY CO ELI (GB) 1998-07-01 EP disclosed
US-5284868-A Naphthopyran derivatives; for autoimmune diseases, cancer ELI LILLY AND COMPANY (US) 1994-02-08 US disclosed
US-5281619-A Administering naphtho(1,2-B)pyran derivatives ELI LILLY AND COMPANY (US) 1994-01-25 US disclosed
EP-0537949-A1 Antiproliferative derivatives of 4H-naphtho 1,2-b pyran LILLY INDUSTRIES LIMITED (GB) 1993-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306396-A1 NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME XDH, CBR3, CBR1 SMN1; SMN2 4287/4885LMNA 3530/4885MAPT 3592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.